StockData
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC (ADAPY) stock

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Adaptimmune Therapeutics's revenue for the twelve months ending Jun 30, 2025 was $65.09M, down 54.0% year over year. For fiscal 2024 it was $178.03M, up 195.3% from the year before. The highest annual figure on record is $178.03M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2024Dec 31, 2024$178.03M+195.3%
FY2023Dec 31, 2023$60.28M+122.0%
FY2022Dec 31, 2022$27.15M+341.5%
FY2021Dec 31, 2021$6.15M+55.4%
FY2020Dec 31, 2020$3.96M+252.8%
FY2019Dec 31, 2019$1.12M-98.1%
FY2018Dec 31, 2018$59.51M+57.3%
FY2017Dec 31, 2017$37.83M+283.3%
FY2015Jun 30, 2015$9.87M+1096.5%
FY2014Jun 30, 2014$825.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2025CQ2 2025Jun 30, 2025$13.68M-89.3%
Q1 FY2025CQ1 2025Mar 31, 2025$7.29M+28.3%
Q4 FY2024CQ4 2024Dec 31, 2024$3.22M+1294.8%
Q3 FY2024CQ3 2024Sep 30, 2024$40.90M+458.8%
Q2 FY2024CQ2 2024Jun 30, 2024$128.23M+2399.6%
Q1 FY2024CQ1 2024Mar 31, 2024$5.68M-88.1%
Q4 FY2023CQ4 2023Dec 31, 2023$231.00K-97.9%
Q3 FY2023CQ3 2023Sep 30, 2023$7.32M+4.5%
Q2 FY2023CQ2 2023Jun 30, 2023$5.13M-7.4%
Q1 FY2023CQ1 2023Mar 31, 2023$47.60M+1231.5%
Q4 FY2022CQ4 2022Dec 31, 2022$11.03M+678.3%
Q3 FY2022CQ3 2022Sep 30, 2022$7.01M+482.5%
Q2 FY2022CQ2 2022Jun 30, 2022$5.54M+78.9%
Q1 FY2022CQ1 2022Mar 31, 2022$3.58M+723.7%
Q4 FY2021CQ4 2021Dec 31, 2021$1.42M-5.7%
Q3 FY2021CQ3 2021Sep 30, 2021$1.20M+0.8%
Q2 FY2021CQ2 2021Jun 30, 2021$3.10M+516.5%
Q1 FY2021CQ1 2021Mar 31, 2021$434.00K-43.0%
Q4 FY2020CQ4 2020Dec 31, 2020$1.50M+106.3%
Q3 FY2020CQ3 2020Sep 30, 2020$1.19M+403.4%
Q2 FY2020CQ2 2020Jun 30, 2020$502.00K+219.7%
Q1 FY2020CQ1 2020Mar 31, 2020$761.00K–
Q4 FY2019CQ4 2019Dec 31, 2019$728.00K-50.8%
Q3 FY2019CQ3 2019Sep 30, 2019$237.00K-99.4%
Q2 FY2019CQ2 2019Jun 30, 2019$157.00K-98.3%
Q1 FY2019CQ1 2019Mar 31, 2019$0-100.0%
Q4 FY2018CQ4 2018Dec 31, 2018$1.48M-65.4%
Q3 FY2018CQ3 2018Sep 30, 2018$40.79M+50.1%
Q2 FY2018CQ2 2018Jun 30, 2018$9.04M+156.7%
Q1 FY2018CQ1 2018Mar 31, 2018$8.20M+186.9%
Q4 FY2017CQ4 2017Dec 31, 2017$4.27M+53.4%
Q3 FY2017CQ3 2017Sep 30, 2017$27.19M+896.5%
Q2 FY2017CQ2 2017Jun 30, 2017$3.52M–
Q1 FY2017CQ1 2017Mar 31, 2017$2.86M–
Q4 FY2015CQ2 2015Jun 30, 2015$2.78M–
Q3 FY2015CQ1 2015Mar 31, 2015$2.73M–

More Adaptimmune Therapeutics figures

See a number that looks wrong?